KB-1394

Panitumumab

33707

Background of Panitumumab

Panitumumab, a monoclonal antibody of notable therapeutic significance, precisely targets the epidermal growth factor receptor (EGFR). Its sophisticated mechanism of action entails a specific binding affinity to the extracellular domain of EGFR, effectively impeding the receptor's activation and subsequent signaling cascade. This interference culminates in the curtailment of cell proliferation and survival, particularly within tumor cells expressing EGFR. Primarily harnessed for the treatment of metastatic colorectal cancer refractory to alternative chemotherapy regimens, panitumumab stands as a pivotal intervention in cases where other therapeutic avenues have proven ineffective.

Specifications

Catalog Number	KB-1394
Antibody Name	Panitumumab
Isotype	Human IgG2,kappa
FC Muations	Wild Type
Target	EGFR
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Easley C, Kirkpatrick P. FRESH FROM THE PIPELINE: Panitumumab. Nat Rev Drug Discov. 2006;5:987–8.
Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6:714–27.